AIMC Topic: Clinical Trials as Topic

Clear Filters Showing 1 to 10 of 256 articles

Integrating mHealth Innovations into Decentralized Oncology Trials.

Journal of medical systems
The integration of mobile health (mHealth) technologies into decentralized clinical trials (DCTs) may represent a paradigm shift in oncology research, offering innovative solutions to longstanding challenges in clinical trial design and execution. mH...

Classification of patients with relapsed/refractory large B-cell lymphoma who do not develop early CRS/NE toxicity using ZUMA clinical trial data.

Journal for immunotherapy of cancer
BACKGROUND: We aimed to develop an actionable and feasible prospective clinical model to estimate toxicity risk to assist chimeric antigen receptor (CAR) T-cell therapy providers with the management of patients with relapsed and/or refractory large B...

Bayesian mediation analysis using patient-reported outcomes from AI chatbots to infer causal pathways in clinical trials.

PloS one
The integration of artificial intelligence (AI) chatbots into clinical trials offers a transformative approach to collecting patient-reported outcomes (PROs). Despite the increasing use of AI chatbots for real-time, interactive data gathering, system...

Why Clinical Trials Will Fail to Ensure Safe AI.

Journal of medical systems
Recent reports have raised concerns about emergent behaviors in next-generation artificial intelligence (AI) models. These systems have been documented selectively adapting their behaviors during testing to falsify experimental outcomes and bypass re...

Predicting therapeutic clinical trial enrollment for adult patients with low- and high-grade glioma using supervised machine learning.

Science advances
Therapeutic clinical trial enrollment does not match glioma incidence across demographics. Traditional statistical methods have identified independent predictors of trial enrollment; however, our understanding of the interactions between these factor...

Evaluating the Impact of AI-Based Model-Informed Drug Development (MIDD): A Comparative Review.

The AAPS journal
Model-informed drug development (MIDD) methods play critical role to ensure development of efficacious, and safe individualized therapies. The application of artificial intelligence/machine learning (AI/ML) within the field of drug development has ex...

Designing Clinical Trials for Patients With Rare Cancers: Connecting the Zebras.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
The field of rare cancer research is rapidly transforming, marked by significant progress in clinical trials and treatment strategies. Rare cancers, as defined by the National Cancer Institute, occur in fewer than 150 cases per million people each ye...

Artificial intelligence in central-peripheral interaction organ crosstalk: the future of drug discovery and clinical trials.

Pharmacological research
Drug discovery before the 20th century often focused on single genes, molecules, cells, or organs, failing to capture the complexity of biological systems. The emergence of protein-protein interaction network studies in 2001 marked a turning point an...

Synthetic Data in Healthcare and Drug Development: Definitions, Regulatory Frameworks, Issues.

CPT: pharmacometrics & systems pharmacology
With the recent and evolving regulatory frameworks regarding the usage of Artificial Intelligence (AI) in both drug and medical device development, the differentiation between data derived from observed ('true' or 'real') sources and artificial data ...

A Machine Learning Approach to Predict Cognitive Decline in Alzheimer Disease Clinical Trials.

Neurology
BACKGROUND AND OBJECTIVES: Among the participants of Alzheimer disease (AD) treatment trials, 40% do not show cognitive decline over 80 weeks of follow-up. Identifying and excluding these individuals can increase power to detect treatment effects. We...